JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on October 30, 2003; DOI: 10.1124/jpet.103.058123


0022-3565/04/3082-502-511$20.00
JPET 308:502-511, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.058123v1
308/2/502    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Darbandi-Tonkabon, R.
Right arrow Articles by Evers, A. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Darbandi-Tonkabon, R.
Right arrow Articles by Evers, A. S.

CELLULAR AND MOLECULAR

Neuroactive Steroid Interactions with Voltage-Dependent Anion Channels: Lack of Relationship to GABAA Receptor Modulation and Anesthesia

Ramin Darbandi-Tonkabon, Brad D. Manion, William R. Hastings, William J. Craigen, Gustav Akk, John R. Bracamontes, Yejun He, Tatiana V. Sheiko, Joseph H. Steinbach, Steven J. Mennerick, Douglas F. Covey, and Alex S. Evers

Departments of Anesthesiology (R.D., B.D.M., W.R.H., G.A., J.R.B., J.H.S., A.S.E.), Molecular Biology and Pharmacology (D.F.C., A.S.E.), and Psychiatry (Y.H., S.J.M.), Washington University School of Medicine, St. Louis, Missouri; and Departments of Pediatrics and Genetics (T.V.S., W.J.C.), Baylor College of Medicine, Houston, Texas

Neuroactive steroids modulate the function of {gamma}-aminobutyric acid type A (GABAA) receptors in brain; this is the presumed basis of their action as anesthetics. In a previous study using the neuroactive steroid analog, (3{alpha},5{beta})-6-azi-3-hydroxypregnan-20-one (6-AziP), as a photoaffinity-labeling reagent, we showed that voltage-dependent anion channel-1 (VDAC-1) was the predominant protein labeled in brain. Antisera to VDAC-1 were shown to coimmunoprecipitate GABAA receptors, suggesting a functional relationship between steroid binding to VDAC-1 and modulation of GABAA receptor function. This study examines the contribution of steroid binding to VDAC proteins to modulation of GABAA receptor function and anesthesia. Photolabeling of 35-kDa protein with [3H]6-AziP was reduced 85% in brain membranes prepared from VDAC-1-deficient mice but was unaffected by deficiency of VDAC-3. The photolabeled 35-kDa protein in membranes from VDAC-1-deficient mice was identified by two-dimensional electrophoresis and electrospray ionization-tandem mass spectrometry as VDAC-2. The absence of VDAC-1 or VDAC-3 had no effect on the ability of neuroactive steroids to modulate GABAA receptor function as evidenced by radioligand ([35S] t-butylbicyclophosphorothionate) binding or by electrophysiological studies. Electrophysiological studies also showed that neuroactive steroids modulate GABAA receptor function normally in VDAC-2-deficient fibroblasts transfected with {alpha}1{beta}2{gamma}2 GABAA receptor subunits. Finally, the neuroactive steroid pregnanolone [(3{alpha},5{beta})-3-hydroxypregnan-20-one] produced anesthesia (loss of righting reflex) in VDAC-1- and VDAC-3-deficient mice, and there was no difference in the recovery time between the VDAC-deficient mice and wild-type controls. These data indicate that neuroactive steroid binding to VDAC-1, -2, or -3 is unlikely to mediate GABAA receptor modulation or anesthesia.


Received August 23, 2003; accepted October 30, 2003.

Address correspondence to: Dr. Alex S. Evers, Department of Anesthesiology, Washington University School of Medicine, 660 S. Euclid Ave, Campus Box 8054, St. Louis, MO 63110. E-mail: eversa{at}notes.wustl.edu




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
T. Bordet, B. Buisson, M. Michaud, C. Drouot, P. Galea, P. Delaage, N. P. Akentieva, A. S. Evers, D. F. Covey, M. A. Ostuni, et al.
Identification and Characterization of Cholest-4-en-3-one, Oxime (TRO19622), a Novel Drug Candidate for Amyotrophic Lateral Sclerosis
J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 709 - 720.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
M. Schumacher, R. Guennoun, A. Ghoumari, C. Massaad, F. Robert, M. El-Etr, Y. Akwa, K. Rajkowski, and E.-E. Baulieu
Novel Perspectives for Progesterone in Hormone Replacement Therapy, with Special Reference to the Nervous System
Endocr. Rev., June 1, 2007; 28(4): 387 - 439.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Xi, R. Liu, G. R. Asbury, M. F. Eckenhoff, and R. G. Eckenhoff
Inhalational Anesthetic-binding Proteins in Rat Neuronal Membranes
J. Biol. Chem., May 7, 2004; 279(19): 19628 - 19633.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.